Mounjaro (tirzepatide) was introduced in 2022 as part of a new generation of type 2 diabetes treatments known as glucagon-like peptide-1 (GLP-1) receptor agonists, which also include Ozempic, Wegovy and Zepbound, the latter of which is a weight loss version of Mounjaro
Many employers now include GLP-1 options in their coverage
However, aGLP1-E2 decreased fasting and fed blood glucose to a greater extent than aGLP1 and iGLP1-E2 alone
The Therapeutic Window: Peak appetite suppression usually occurs between months 3 and 4
As a registered dietitian, I emphasize to my clients that lasting and safe weight loss is built on the foundation of following a healthy and balanced diet, being physically active, getting sufficient sleep, and managing stress
Key Takeaways at a Glance Bottom line: Most GLP-1 fatigue is practical, not mysterious: appetite drops, intake shrinks, fluids/electrolytes slip, and GI side effects disrupt routines